Skip to content

Study · Observational study · n = 40 · 2024

4 results

Liraglutide and not lifestyle intervention reduces soluble CD163 after comparable weight loss in obese participants with prediabetes or type 2 diabetes mellitus.

Grannes H, Ueland T, Simeone P, Liani R, Guagnano MT, Aukrust P, Michelsen AE, Birkeland K, di Castelnuovo A, Cipollone F, Consoli A, Halvorsen B, Gregersen I, Santilli F

Cardiovascular diabetology29 Apr 2024Cited by 11 (Europe PMC)

PMID38685051 (opens in a new tab)PMCIDPMC11059692 (opens in a new tab)DOI10.1186/s12933-024-02237-8 (opens in a new tab)PepBankPUB-38685051
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

BackgroundThe GLP-1 receptor agonist liraglutide is used to treat hyperglycemia in type 2 diabetes but is also known to induce weight loss, preserve the beta cell and reduce cardiovascular risk. The mechanisms underlying these effects are however still not completely known. Herein we explore the effect of liraglutide on markers of immune cell activity in a population of obese individuals with prediabetes or newly diagnosed type 2 diabetes mellitus.MethodPlasma levels of the monocyte/macrophage markers, soluble (s)CD163 and sCD14, the neutrophil markers myeloperoxidase (MPO) and neutrophil gelatinase-associated lipocalin (NGAL),the T-cell markers sCD25 and T-cell immunoglobulin mucin domain-3 (sTIM-3) and the inflammatory marker TNF superfamily (TNFSF) member 14 (LIGHT/TNFSF14) were measured by enzyme-linked immunosorbent assays in obese individuals with prediabetes or diabetes diagnosed within the last 12 months, prior to and after comparable weight loss achieved with lifestyle changes (n = 20) or liraglutide treatment (n = 20), and in healthy subjects (n = 13).ResultsAt baseline, plasma levels of the macrophage marker sCD163, and the inflammatory marker LIGHT were higher in cases as compared to controls. Plasma levels of sCD14, NGAL, sTIM-3 and sCD25 did not differ at baseline between patients and controls. After weight reduction following lifestyle intervention or liraglutide treatment, sCD163 decreased significantly in the liraglutide group vs. lifestyle (between-group difference p = 0.023, adjusted for visceral adipose tissue and triglycerides basal values). MPO and LIGHT decreased significantly only in the liraglutide group (between group difference not significant). Plasma levels of MPO and in particular sCD163 correlated with markers of metabolic dysfunction and inflammation. After weight loss, only sCD163 showed a trend for decreased levels during OGTT, both in the whole cohort as in those of liraglutide vs lifestyle group.ConclusionWeight loss following treatment with liraglutide was associated with reduced circulating levels of sCD163 when compared to the same extent of weight loss after lifestyle changes. This might contribute to reduced cardiometabolic risk in individuals receiving treatment with liraglutide.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyMechanism

    In obese adults with prediabetes or type 2 diabetes, plasma sCD163 fell more with liraglutide than with lifestyle change after comparable weight loss.

    In plain wordsIn obese adults with prediabetes or diabetes, a blood marker of macrophage activity fell more with liraglutide than with lifestyle change at similar weight loss.

    Peptide
    Liraglutide
    Outcome
    DecreasePlasma sCD163 after weight loss
    Study

    n = 40

    Comparator
    Lifestyle intervention
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After weight reduction following lifestyle intervention or liraglutide treatment, sCD163 decreased significantly in the liraglutide group vs. lifestyle (between-group difference p = 0.023, adjusted for visceral adipose tissue and triglycerides basal values).
    1 context sentence
    Summary · context
    obese individuals with prediabetes or diabetes diagnosed within the last 12 months, prior to and after comparable weight loss achieved with lifestyle changes (n = 20) or liraglutide treatment (n = 20), and in healthy subjects (n = 13)
  2. 02HumanObservational studyMechanism

    In obese adults with prediabetes or type 2 diabetes, plasma MPO decreased significantly only in the liraglutide group; the between-group difference was not significant.

    In plain wordsIn obese adults with prediabetes or diabetes, a neutrophil marker fell with liraglutide but not lifestyle change; the between-group difference was not significant.

    Peptide
    Liraglutide
    Outcome
    DecreasePlasma MPO after weight loss
    Study

    n = 20

    Comparator
    Lifestyle intervention
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MPO and LIGHT decreased significantly only in the liraglutide group (between group difference not significant).
    1 context sentence
    Summary · context
    obese individuals with prediabetes or diabetes diagnosed within the last 12 months, prior to and after comparable weight loss achieved with lifestyle changes (n = 20) or liraglutide treatment (n = 20), and in healthy subjects (n = 13)
  3. 03HumanObservational studyMechanism

    In obese adults with prediabetes or type 2 diabetes, plasma LIGHT decreased significantly only in the liraglutide group; the between-group difference was not significant.

    In plain wordsIn obese adults with prediabetes or diabetes, an inflammation marker fell with liraglutide but not lifestyle change; the between-group difference was not significant.

    Peptide
    Liraglutide
    Outcome
    DecreasePlasma LIGHT (TNFSF14) after weight loss
    Study

    n = 20

    Comparator
    Lifestyle intervention
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MPO and LIGHT decreased significantly only in the liraglutide group (between group difference not significant).
    1 context sentence
    Summary · context
    obese individuals with prediabetes or diabetes diagnosed within the last 12 months, prior to and after comparable weight loss achieved with lifestyle changes (n = 20) or liraglutide treatment (n = 20), and in healthy subjects (n = 13)
  4. 04HumanObservational studyMechanism

    After weight loss, sCD163 showed only a trend to lower levels during the OGTT, in the whole cohort and in the liraglutide versus lifestyle comparison.

    In plain wordsAfter weight loss, a macrophage marker showed only a trend to fall during a glucose test, with liraglutide compared with lifestyle change.

    Peptide
    Liraglutide
    Outcome
    No significant changesCD163 during OGTT after weight loss
    Study

    n: not reported in source

    Comparator
    Lifestyle intervention
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After weight loss, only sCD163 showed a trend for decreased levels during OGTT, both in the whole cohort as in those of liraglutide vs lifestyle group.
    1 context sentence
    Summary · context
    obese individuals with prediabetes or diabetes diagnosed within the last 12 months, prior to and after comparable weight loss achieved with lifestyle changes (n = 20) or liraglutide treatment (n = 20), and in healthy subjects (n = 13)

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.